Podcasts about weill cornell medical college

Dr. Robert Leahy, Founder and Director of the American Institute for Cognitive Therapy, an award-winning clinician, clinical professor of psychology at Weill Cornell Medical College, keynote speaker, and author and editor of 29 books, including The Worry Cure, joins me on this episode. Dr. Leahy has been featured in major media outlets including The New York Times Sunday Magazine, Forbes, Fortune, Newsweek, and Psychology Today.

Send us Fan MailEvery year, thousands of newborns suffer devastating brain injury during birth - and despite decades of research, there are still no approved drug therapies for Hypoxic Ischemic Encephalopathy (HIE). But one biotech company believes it may finally have a solution.Dr. Howard Berman, Ph.D. is Chief Executive Officer and Chairman of ReAlta Life Sciences ( https://realtalifesciences.com/ ), a clinical-stage biotechnology company developing novel therapies for severe inflammatory diseases.Dr. Berman brings a unique background spanning neuroscience, pharmacology, medical affairs, technology transfer, and biotech entrepreneurship. He earned his Ph.D. in Pharmacology and Neuroscience from Weill Cornell Medical College, where his research focused on pain and temperature processing in the human brain using functional MRI. Over the course of his career, he has held roles at Novartis, Eli Lilly and Company, and AbbVie, working across oncology, neuroscience, immunology, and business development.Dr. Berman later went on to found Coya Therapeutics, a company focused on regulatory T-cell biology and neurodegenerative disease, and has built a reputation for identifying and advancing novel therapeutic approaches at the intersection of science and translational medicine.Today, Dr. Berman is leading ReAlta at a particularly important moment for the company. ReAlta recently announced a $40 million financing round to support the continued development of its lead therapeutic candidate, pegtarazimod, for the treatment of Hypoxic Ischemic Encephalopathy, or HIE.HIE is a devastating condition caused by a lack of oxygen and blood flow to the brain during or around the time of birth. It remains one of the leading causes of neonatal mortality and long-term neurological disability worldwide, often resulting in conditions such as cerebral palsy, epilepsy, and cognitive impairment. Despite decades of research, there are currently no approved drug therapies specifically targeting the underlying inflammatory injury associated with HIE.Pegtarazimod represents a novel approach. Derived from a naturally occurring viral peptide, the therapy is designed to modulate two major upstream drivers of inflammatory damage - the complement system and neutrophil-mediated inflammation. Rather than focusing on a single downstream pathway, the strategy aims to intervene earlier in the inflammatory cascade that contributes to ongoing brain injury following hypoxic events.The company's ongoing Phase 2 STAR trial is currently evaluating pegtarazimod in newborns with moderate to severe HIE undergoing therapeutic hypothermia, which remains the current standard of care.In this conversation, we discuss:- the biology and clinical burden of HIE,- why past therapeutic approaches have struggled,- the scientific origins of pegtarazimod,- how virus-derived peptides may open new approaches to immune modulation,- and what success could ultimately mean for neonatal medicine and inflammatory disease more broadly.#NeonatalCare #HIE #HypoxicIschemicEncephalopathy #BrainInjury #NewbornHealth #Biotech #Inflammation #Neuroscience #NICU #DrugDevelopment #Pharma #HealthcareInnovation #ComplementSystem #Immunology #RareDisease #ClinicalTrials #Pediatrics #MedicalInnovation #ReAlta #HowardBerman #FutureOfMedicine #PrecisionMedicine #Neuroprotection #LifeSciences #ProgressPotentialPossibilitiesSupport the show

Back by popular demand, Dr. Gail Saltz, Clinical Associate Professor of Psychiatry at the New York Presbyterian Hospital, Weill-Cornell Medical College and a psychoanalyst with the New York Psychoanalytic Institute returns to discuss all things aging parents. She highlights the checklist of things everyone should have prepared, how to safeguard your parents from scammers, and how and when it's time to move your parent into a facility without breaking the bank. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The conversation is in English, after a short introduction in Swedish. Den prisbelönta amerikanska författaren är aktuell med "En bok om spöken: en kärleksmemoar" – ett ömsint porträtt av sitt liv tillsammans med sin bortgångna man, författaren och filmskaparen Paul Auster. Siri Hustvedt (född 1955) är bosatt i Brooklyn, New York och är verksam som författare, essäist och forskare. Hon är fil.dr i engelsk litteratur vid Columbia University, undervisar i psykiatri vid Weill Cornell Medical College och har publicerat såväl romaner som essäer och vetenskapliga artiklar inom neurovetenskap, litteratur, filosofi och bildkonst. Bland Siri Hustvedts mest kända verk finns romanerna "Vad jag älskade", "Den lysande världen" och essäsamlingen "The Delusions of Certainty". Hon har mottagit flera internationella priser och utmärkelser och hennes böcker har översatts till 29 språk. Ingrid Elam är litteraturvetare, kritiker och essäist. Hon har medverkat i flera olika litteraturhistorieprojekt och antologier och varit kulturchef för Göteborgsposten och Dagens Nyheter. Sedan 2012 är Ingrid Elam dekan vid konstnärliga fakulteten på Göteborgs universitet. Hon har givit ut hyllade "Romanens segertåg" och är aktuell med "Läsa liv: Biografin, en levnadsteckning". I samarbete med Norstedts förlag. Från 31 mars 2026 Jingel: Lucas Brar

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Monty Pal: Hello everyone and welcome to the ASCO Daily News Podcast. I'm your host, Monty Pal. I'm a medical oncologist, underline medical oncologist, a professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. You're going to understand why I underlined "medical oncologist" there. I'm actually on the line today with two amazing hematologists. Today, we're going to actually explore treatments for high-risk smoldering multiple myeloma following the FDA's approval last year of daratumumab for the first-ever treatment of this indication. Now, this is based on the AQUILA trial, and this represents a huge shift in our traditional watch-and-wait approach to active disease interception. We're going to consider whether this landmark trial published in The New England Journal translates to day-to-day practice. I think it does, and we'll certainly make an argument for that. And I'm so fortunate today to have two internationally acclaimed experts here in the conversation: Dr. Vincent Rajkumar, senior author on the manuscript, and Dr. Saad Usmani, also an expert in his own right in myeloma. Dr. Rajkumar is the lead investigator of the AQUILA study. He's a professor of medicine and consultant in the divisions of hematology and hematopathology at the Mayo Clinic in Rochester, Minnesota. He actually chairs the Myeloma, Amyloidosis, Dysproteinemia Program. He is also editor-in-chief of the Blood Cancer Journal. Dr. Usmani, he and I actually go way, way back. We actually did the AACR Molecular Biology in Clinical Oncology course, I want to say in 2006, so this is our 20-year anniversary, Saad. He's the chief of the myeloma service at the MSK Cancer Center and a professor of medicine at the Weill Cornell Medical College in New York.  Saad, Vincent, welcome. Dr. Saad Usmani: Thank you so much for having me, Monty. Dr. Vincent Rajkumar: Yeah, thanks, Monty. A pleasure to be here. Dr. Monty Pal: Thanks. And just a quick note for our listeners, all of our disclosures are available in the transcript of this episode. First off, Saad, did I get that right? Was it 2006 when we did that course together? Dr. Saad Usmani: Yeah, 20 years. We are coming up to our 20-year anniversary. It's remarkable to have seen our careers move the way they have, Monty. Dr. Monty Pal: Oh my gosh. And for all the fellows who are on the line, that AACR Molecular Biology and Clinical Oncology course, it's sometimes overlooked. Wonderful primer on translational science. Okay, now we're going to get to the heart of the matter here, the AQUILA trial. So this was a study, Vincent, that you led. I wonder if you'd walk us through the primary endpoints in the study. What are we looking at in the AQUILA trial specifically? Dr. Vincent Rajkumar: Thanks so much. Again, as you mentioned, smoldering multiple myeloma has just been a condition that we watch and wait. And the first thing that I want to clarify here is that the AQUILA trial is looking at only a subset of smoldering multiple myeloma. That is the high-risk smoldering multiple myeloma. It was defined the way high-risk smoldering myeloma was defined at the time the trial was designed. It randomized 390 patients. One arm got daratumumab single agent in an attempt to delay progression to active myeloma and possibly prolong survival. And the other arm was the traditional observation. The primary endpoint, therefore, was time to active multiple myeloma. Other endpoints included time to when patients needed to start therapy for active multiple myeloma, which can vary based on physician judgment, and overall survival. Of course, response rate, complete response rate, and others were also endpoints. Dr. Monty Pal: That's interesting. And you know, I wanted you to riff a little bit on this definition of high-risk smoldering myeloma. Can you tell our audience how that's sort of evolved over the years? Dr. Vincent Rajkumar: Yes. I mean, if you step back, monoclonal gammopathy of undetermined significance has only a 1% per year risk of progression. Smoldering multiple myeloma, all comers have a 10% per year risk of progression. And over the years, trials have been done in the whole population, and then more recently, we felt we should really focus on the people with high-risk smoldering, defined as a 50-50 risk of progression in 2 years. That's like a 25% per year risk of progression in the first 2 years, which is a very high risk for the patient and something that would justify prophylactic intervention. And that definition initially was based on just high levels of monoclonal protein like more than 3 grams, the IgA subtype of myeloma, the suppression of uninvolved immunoglobulins. Others have used bone marrow flow cytometry markers, cytogenetics. Those combinations of factors were available at the time the AQUILA trial was designed, and a select combination was used. Later on, we found that we could match almost all of that in a very simple risk stratification using just the percentage of bone marrow plasma cells, the level of the M-spike, and the free light chain ratio, all three of which are available to all patients with smoldering at the time of diagnosis. So you don't need any special testing. So more than 20% plasma cells, more than 20 for the light chain ratio, and more than 2 grams for the M-spike. If someone has any two of the three, that is high-risk smoldering multiple myeloma according to the IMWG, but that definition, of course, came in 2020 after the AQUILA trial completed accrual. Dr. Monty Pal: That's interesting because this sort of flips the traditional paradigm where biomarkers get more and more complex as time goes on. Am I right in saying this sort of simplifies things a little bit? It uses standard laboratory or clinical parameters to gauge this category? Dr. Vincent Rajkumar: Absolutely. People were using suppression of uninvolved immunoglobulins, and those levels are not standardized, often vary by race. Also, the other aspect was the abnormal plasma cells on flow cytometry. Again, labs define it differently. So this makes it much more simple. But the IMWG also did a separate exploratory cohort within that paper where we added cytogenetics and we added scoring systems to improve on this further. So it simplified it for regular clinical practice and for like trials. But if you have a patient in front of you, the IMWG paper also has more complex scoring systems where you can take more than 20; 21 is more than 20, so is 51. And so, you can use the actual numbers that a patient has, additional variables like cytogenetics, and get a more refined estimate of what is the true risk of progression. Dr. Monty Pal: That's really helpful. Now, you told us about the primary endpoints, you've helped us define high-risk smoldering myeloma. Can you give us a sense of the top-line results from AQUILA? Dr. Vincent Rajkumar: Yes, I think the most important one was the primary endpoint, time to multiple myeloma, was at 5 years, the progression-free survival was 63% in the daratumumab arm compared to 41% in the observation arm. So, you know, approximately 60% of patients in the observation arm had already progressed by 5 years. And that number was about 40% for the daratumumab arm. We also looked at time to starting myeloma therapy, which is clinically actually quite meaningful because, you know, myeloma therapy means patients get a quadruplet for induction, they get stem cell transplant, they get endless maintenance, they get ongoing therapy virtually for the entire duration. So, preventing the need for myeloma therapy is in and of itself, I think, a major endpoint. And that at 3 years, 40% of people in the observation arm required full myeloma therapy compared to only 20% in the daratumumab arm. So there's a significant reduction in the risk of developing active myeloma as well as the need for myeloma therapy by using a time-limited 3 years of daratumumab single agent. Dr. Monty Pal: Perfect summary of the results. And maybe, Saad, I'm going to bring you into the conversation now. How does this sort of influence your day-to-day practice for smoldering myeloma? Is this something that you've incorporated for that high-risk subset? Dr. Saad Usmani: Thank you, Monty, and I agree. I think that's a really nice summary from Vincent. This study is very important for several reasons. It's actually the third clinical trial that has demonstrated that patients who are in the high-risk smoldering myeloma category benefit from an early intervention that delays the progression to active myeloma or to end-organ damage. And so having a nuanced discussion with our patients in the clinic becomes very important. Having this discussion around as an option becomes very important. And like Vincent said, when we look at that high-risk smoldering myeloma patient population, someone who has 22, 23% plasma cells versus, you know, 45, 50, you know, it's going to be a different discussion each time. But I think it's a very important first step. And I think this sets up the stage for us to design clinical trials where we can ask other questions on what would be better than daratumumab alone in terms of delaying progression in these patients. The other thing that I do want to highlight, and Vincent touched upon this a little bit, that the treatment in this clinical trial was for a fixed duration of treatment. So it was not forever treatment. This is maybe something that Vincent, you can even comment on a little bit more because the question we get after having this discussion is, "Okay, what do we do with patients who are going to be progressing to active myeloma?" Whether we can utilize anti-CD38 therapies for those. So Vincent, I would love your take on this too. Dr. Vincent Rajkumar: Yeah, I think, you know, the main philosophical change for me was previously, the thing was 'don't treat', and now for high-risk smoldering multiple myeloma, the question is, is daratumumab the best treatment or can we do something better? And those trials are thankfully ongoing. One of them has already completed accrual, isatuximab-len-dex versus len-dex. And another one is ongoing in ECOG, almost close to finishing accrual. And in the future, we'll be trying to see if we can use early intervention to even cure and prevent progression altogether.  So we are in this phase where we have one approved regimen, one approved drug, and we are not sure whether we can improve on that. The question is, "is a myeloma-like therapy better than monotherapy" would be the next question, and then what would we do further beyond that? In this context, whenever we have patients like this, one of the questions that comes up, as Saad mentioned, is how does this affect newly diagnosed myeloma therapy if somebody has been treated for smoldering and things like that? How will they be considered for clinical trials? Would they be considered as relapse myeloma or still newly diagnosed myeloma? And those are important discussions for clinical trialists to keep in mind, but I think for clinical practice, your duty is to the patient in front of you. If they have high-risk smoldering myeloma and there's data that there's treatments that can delay progression significantly, delay the need for myeloma therapy significantly, that's the highest priority. We'll cross that bridge.   There are so few patients going on clinical trials right now that if such a patient were to later on progress and wants to enter in a newly diagnosed myeloma trial later, years later, we can figure that out later. I feel like the most important discussion is what to do for that patient today. I still prefer a clinical trial if one was available. If one was not available, I'd prefer early intervention, but have an informed discussion with the patient because some of them may wish to delay therapy still. Some of them may have very borderline numbers that you want to watch them closely. Some of them may be having other comorbidities that prevent need for therapy. Some of them maybe have had the smoldering for a long time and you already know it's stable. So a lot of factors go in, and I think it's not a one-size-fits-all. Dr. Monty Pal: This is a terrific discussion, and you know, it sort of segues into maybe a question around biology. And this is something I was going to get to a little bit later, but Saad, I'm glad you brought it up. I'll liken it to the only thing I know, which is kidney cancer. So, you know, in kidney cancer, we use checkpoint inhibitors as adjuvant therapy. And there's this question of whether or not it breeds some resistance in the localized setting to ultimately what the patient might potentially be exposed to in the metastatic setting. Tell me your thoughts on this, Vincent, then maybe Saad separately. If you treat a patient with daratumumab in this high-risk smoldering setting, could it theoretically sort of limit options in the refractory setting now that we have regimens like DRBD that are kind of being utilized, or daratumumab with teclistamab? Vincent, I'll throw that to you first. Dr. Vincent Rajkumar: This is a great question, and it's usually asked when we've done the lenalidomide trials actually. We try to put the question back. If that was your concern, how would you actually solve it? Is it really biology that's going to answer that? Or is it a randomized trial? So the experiment has been done three times now where early intervention has been given. And if there was some detriment because of that, that would be reflected in the overall survival. In all three trials, there's no such detriment seen. In the first lenalidomide-dex trial, there was an improvement in overall survival. In the AQUILA trial again, the confidence interval doesn't cross one, and patients had better long-term survival on AQUILA, but certainly not less. We've also examined PFS2 data, and that doesn't seem to be affected. So yes, there is a theoretical concern, and that concern cannot be allayed for new treatments which we have not even tried, like tec-dara, and whether that effect would be there or not. But so far, I don't see it. And I think the onus is on proof of that in order to prevent people from getting early therapy. Dr. Monty Pal: Yeah. Saad, your thoughts on that? And before you jump in, I'll mention, we're kind of taking the same approach in kidney cancer, we're trying to really do studies to see whether or not, you know, immunotherapy rechallenge in these contexts, you know, really lends any substantial benefit. So far, the results have been interesting. I don't think we have enough numbers as yet to capture the impact of adjuvant therapy as it translates to metastatic, but I see so many similarities between the scenarios that you're facing in myeloma and what we're facing in RCC. Saad, your thoughts? Dr. Saad Usmani: Thanks, Monty. I'll go back to something that Vincent alluded to a few minutes ago about the way that we risk-stratify patients within smoldering myeloma. Right now, we are relying more on a disease burden-based stratification looking at the percentage of plasma cells in the bone marrow, the monoclonal protein, as well as the involved light chain versus the uninvolved light chain ratio. However, there are efforts underway to actually incorporate genomics into that schema and try to refine that definition of high-risk smoldering. And there have been two papers that came out in the latter half of last year. In fact. Dr. Rajkumar and I are co-senior authors on one effort where we can identify genomic myeloma in patients in precursor conditions. One of the key things that came out of that effort was that within the high-risk smoldering myeloma category, about 90% of the patients are genomically myeloma. So this whole debate of whether we need to intervene for those patients, I think, you know, we have sufficient biologic evidence that yes, we need to intervene for those patients.  I think that the next real step, like Vincent stated, is how do we intervene in those patients? And those clinical trials kind of are ongoing. We will probably need to have more validation of those genomic models being incorporated, but that's what I see in the future. I wouldn't be concerned for the patients being seen today with that query about the disease biology evolving because if I'm seeing a patient today in March of the first quarter of 2026 and offering them monotherapy daratumumab in their high-risk smoldering situation for the next 3 years and then they progress to myeloma after another couple of years, we are talking about what would be the treatment options for them in 2031, 2032. So I think the field is moving so fast, we have a lot of novel therapies coming into that frontline setting rapidly, so our options at that time would be very different. So, you know, I just wanted to kind of set up the stage for saying, you know, our tools are getting better in delineating which patients will need that intervention. And then eventually, I think, you know, we'll have much better options for newly diagnosed myeloma patients at the time when they need it in the future. Dr. Monty Pal: Just absolutely brilliant, absolutely brilliant. I love that summary. I think that you're absolutely right in saying that, you know, you've got to think about what you're going to do for that patient sort of in the moment, what's going to optimize their outcome and agree that the landscape is evolving very rapidly.  I'd be remiss, Saad, if I didn't ask you about something that I've been following in terms of your career trajectory. You've developed quite a reputation for your leadership in trials looking at CAR T-cell therapies for myeloma. Can you give us a sense of where that stands in broad terms? Dr. Saad Usmani: Certainly, Monty. I think the CAR Ts have slowly made their way from late relapse to early relapse. And now we have clinical trials that have completed accrual in the frontline setting comparing them to standard-of-care treatment for both older myeloma patients or transplant-ineligible patients, as well as younger transplant-eligible patients where we're actually trying to replace transplants with BCMA-directed CAR T-cell therapies. The nuance there would be we want to equal or better the survival outcomes that we've accomplished without compromising on the safety side of things for patients. Those therapies are moving into earlier lines. And more excitingly, you know, that's just the first wave of CARs. The next wave of CAR technology is coming, and it's going to be in vivo CARs where we may not need lymphodepleting chemotherapy, we may not even need as stringent regulatory nuances that we do for cellular therapies today. So, you know, I think the field is moving rapidly, and it's going to be a very interesting landscape to see over the next 5 to 6 years. Dr. Monty Pal: Yeah, you know, it's so interesting. I know in the solid tumor space, we're trying to replicate the success that you've had with CAR T and bispecifics, and I do see some light at the end of the tunnel. I'm seeing some really promising agents being developed, but clearly, we have so much to learn from our colleagues in hematology. Well, I have to tell you, this has just been a phenomenal conversation. Vincent, congratulations on your leadership of the AQUILA trial. Clearly, a big paradigm shift in the field. Saad, thank you for offering your expert insights and really giving us also a glimpse at the future of myeloma. Really appreciate having you both on the podcast today. Dr. Vincent Rajkumar: Thank you, Monty. Dr. Saad Usmani: Thank you so much. Dr. Monty Pal: And thank you so much to our listeners for your time today. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Monty Pal    @montypal   Dr. Vincent Rajkumar @VincentRK Dr. Saad Z. Usmani @szusmani   Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Vincent Rajkumar: Honoraria: Research to Practice, Medscape Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date Dr. Saad Usmani: Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, Abbvie, Bristol-Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi Research Funding: Janssen Oncology, Bristol-Myers Squibb, K36 Therapeutics, Abbvie, Regeneron  

So… what even counts as “BPD” anymore?Last week, we explored how the Alternative Model for Personality Disorders (AMPD) moves away from strict categories. This week, we're taking it further:What does BPD actually look like in this model, and do you even need the label at all?We break down the core of BPD through self and interpersonal functioning, how traits shape the “borderline” pattern, and why diagnoses like BPD and NPD might not be as separate as people think. If you've ever felt like the DSM didn't fully capture your experience, this might hit differently.This is Part 2 of a 2-part series.⸻Featuring:Dr. Carla Sharp — Clinical psychologist and Professor at the University of Houston. Director of the Developmental Psychopathology Lab, with a focus on personality disorders, mentalization, and adolescent development.Dr. Frank Yeomans — Clinical Professor of Psychiatry at Weill Cornell Medical College and Director of Training at the Personality Disorders Institute. Internationally recognized for his work in Transference-Focused Psychotherapy (TFP).Dr. Alex Stein — Clinical psychologist, researcher, and advocate known for her work on attachment patterns and “favorite person” relationships in BPD.⸻Subscribe to see what these traits actually look like from a lived experience perspective!

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to report independent clinical validation of the company's Phase 2 SkinJect® dataset by Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized leader in dermatology and skin cancer research. According to Dr. Rao's independent assessment, the study results are clinically meaningful and “decision-grade,” supporting Medicus Pharma's continued development of the SkinJect platform and future regulatory engagement. His validation adds significant credibility to the dataset as the company advances toward later-stage trials. The SKNJCT-003 trial is a randomized, double-blind, three-arm Phase 2 study designed to evaluate microneedle-mediated delivery of doxorubicin in patients with nodular basal cell carcinoma. The study compares the therapeutic approach against a biologically active device-only control, providing a rigorous framework to isolate the incremental benefit of the drug component while also assessing both visual (clinical) and histological clearance endpoints. Dr. Rao emphasized that the trial design enables a clear understanding of treatment effectiveness, combining real-world clinical observations with detailed pathological analysis. He noted that the findings carry important implications for patient care, particularly in reducing reliance on invasive procedures. One of the most compelling outcomes highlighted was that approximately three out of four treated lesions achieved visual tumor clearance. This suggests that a significant number of patients could potentially avoid immediate surgical intervention, offering a less invasive treatment alternative for certain forms of skin cancer. Dr. Rao, a dermatologist, dermatopathologist, Mohs surgeon, and clinical investigator, brings extensive expertise in skin oncology. He serves as Professor of Dermatology and Pathology and Director of Clinical Research at Rutgers Robert Wood Johnson Medical School, with additional academic roles at Weill Cornell Medical College and California Health Sciences University. The independent validation strengthens Medicus Pharma's position as it continues to develop SkinJect as a novel, minimally invasive treatment option, with the potential to reshape how certain skin cancers are managed in clinical practice #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Dermatology #SkinCancer #BasalCellCarcinoma #OncologyInnovation #Biotech #DrugDelivery #Microneedle #Doxorubicin #ClinicalResearch #HealthcareInnovation #MedicalBreakthrough #ProactiveInvestors

Toxicology lives at the intersection of chemistry, medicine, and survival—where everyday exposures and rare threats alike can shape human health in profound ways. From the silent danger of carbon monoxide to the rapid lethality of cyanide, and the complex line between poison and remedy, this conversation unpacks how toxins move through and impact the body. We explore the ongoing opioid crisis, the life-saving role of naloxone, and how clinicians respond in moments where minutes matter most. Along the way, the lens widens to include venom, environmental exposures, and even the realities of bioterrorism—revealing just how much of our world is defined by what we can't see. In this episode, we are joined by Dr. Andaleeb Hamid Raja, MD, a double board-certified emergency medicine physician and medical toxicologist and assistant professor of medicine based in New York City. Dr. Raja received her MD from Saba University School of Medicine and completed her Emergency Medicine Residency at Lincoln Medical Center and Medical Toxicology Fellowship at the University of Pittsburgh. Currently, Dr. Raja is an Assistant Professor of Medicine at Weill Cornell Medical College and is the Assistant Program Director of Emergency Medicine Residency at NYC Health + Hospitals/Lincoln.Follow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz (Host): Instagram, YouTube

Cardiologist and professor Dr. Mary Roman of New York Presbyterian-Weill Cornell Medical Center and Weill Cornell Medical College joins Heart of The East End Gianna Volpe to talk about aortic aneurysms, as well as The Marfan Foundation, amidst the spring fund drive for Long Island's only local NPR radio station. All donations made to WLIWFM.org or by phone at 800-262-0717 go right to work creating and curating a listening experience that is Long Island's own with an opportunity for listeners to leave a message on listener line to let us know why they love WLIW-FMListen to the playlist on Apple MusicWatch the interview on WLIW-FM YouTube

What if Borderline Personality Disorder isn't just a checklist of symptoms?In this episode of The BPD Bunch, we explore the Alternative Model for Personality Disorders (AMPD), a framework that shifts how we understand BPD from a set of categories to patterns of functioning, severity, and relationships.Joined by leading clinicians in the field, we break down what's changing, why it matters, and how this model could reshape diagnosis, treatment, and stigma.This is Part 1 of a 2-part series.⸻Featuring:Dr. Carla Sharp — Clinical psychologist and Professor at the University of Houston. Director of the Developmental Psychopathology Lab, with a focus on personality disorders, mentalization, and adolescent development.Dr. Frank Yeomans — Clinical Professor of Psychiatry at Weill Cornell Medical College and Director of Training at the Personality Disorders Institute. Internationally recognized for his work in Transference-Focused Psychotherapy (TFP).Dr. Alex Stein — Clinical psychologist, researcher, and advocate known for her work on attachment patterns and “favorite person” relationships in BPD.⸻Subscribe for Part 2 where we break down what BPD actually looks like under this model.

Professor Jonathan E. Rosenberg, MD, serves as the Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Centre (MSKCC). He is a prolific researcher and author, holding multiple titles including Attending Physician at MSKCC, Professor of Medicine at Weill Cornell Medical College, and the Enno W. Ercklentz Chair in Genitourinary Oncology.Today, Jonathan explores metastatic urothelial cancer, discussing the current landscape and available treatment options, emphasising that a single approach may not be suitable for all patients. We also cover early bladder cancer and non-invasive muscle-invasive bladder cancer (NIMBC). For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Dr. Gail Saltz, Clinical Associate Professor of Psychiatry at Weill Cornell Medical College, joins Kelly to address aging parents, how to approach their care, how to divide the labor, and how to protect yourself from caregiver burnout. Plus, Dr. Gail discusses how to get your parents to listen and how to address the whys and the realities of the situation! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dhruv Khullar, practicing physician, associate professor of health policy and economics at Weill Cornell Medical College and contributing writer at The New Yorker, talks about the effect GLP-1 drugs, like Ozempic, are having on curbing addictions and what researchers are studying about that phenomenon.Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images

Send us a textNavigating Childhood Tics and Tourette Syndrome: Expert Insights with Dr. GreenbergIn this  episode, we sit down with Dr. Greenberg, director of the pediatric psychiatry OCD and Tic disorders program in Boston, to discuss the complexities of childhood tics and Tourette Syndrome. Dr. Greenberg shares his extensive expertise and personal experiences to help parents understand what tics are, how they manifest, and their natural progression. He provides insights on effective treatments such as CBIT therapy and when medication might be necessary. Additionally, Dr. Greenberg emphasizes the importance of differentiating between normal tics and those that may indicate other co-occurring conditions like ADHD and OCD. This episode is a must-watch for parents seeking reassurance and practical advice on managing their child's tics.Erica Greenberg, M.D. is an assistant Professor in Psychiatry at Harvard Medical School and a child/adolescent psychiatrist at Massachusetts General Hospital (MGH) where she is the Director of the Pediatric Psychiatry OCD and Tic Disorders Program. Dr. Greenberg is also a co-Director of the MGH Tourette Association of America (TAA) Center of Excellence and the co-president of the Medical Advisory Board of the TAA. Her interests include Tourette syndrome (TS), OCD, “Tourettic OCD,” ADHD, body-focused repetitive behavior disorders, and other Tourette syndrome spectrum conditions. She has authored several peer-reviewed manuscripts on TS, OCD, and related disorders, and has presented on these conditions nationally and internationally. Dr. Greenberg graduated from Weill Cornell Medical College with Alpha Omega Alpha honors, and completed her general psychiatry residency at Harvard Longwood and her child/adolescent fellowship training at MGH.Contact Dr Greenberg: MassGeneral Brigham; Massachusetts General Hospital for ChildrenPediatric Psychiatry OCD and Tic Disorders ProgramEmail: MGHPediOCDTics@partners.org617-643-2780Your Child is Normal is the trusted podcast for parents, pediatricians, and child health experts who want smart, nuanced conversations about raising healthy, resilient kids. Hosted by Dr. Jessica Hochman — a board-certified practicing pediatrician — the show combines evidence-based medicine, expert interviews, and real-world parenting advice to help listeners navigate everything from sleep struggles to mental health, nutrition, screen time, and more. Follow Dr Jessica Hochman:Instagram: @AskDrJessica and Tiktok @askdrjessicaYouTube channel: Ask Dr Jessica If you are interested in placing an ad on Your Child Is Normal click here or fill out our interest form.-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditi...

Protein bars, shakes, and snacks now line grocery shelves, turning a basic nutrient into a booming food trend. Alice Callahan, a nutrition and health reporter for The New York Times and and Dr. Rekha Kumar, an associate professor of Clinical Medicine and Attending Endocrinologist at the Weill Cornell Medical College explains why protein matters for the body, how much people actually need, and how food companies transformed it into big business.

In this episode, Frank A. Cordasco, MD, MS, Professor of Orthopaedic Surgery at Weill Cornell Medical College and Attending Surgeon at the Hospital for Special Surgery, joins the Becker's Spine and Orthopedics Podcast to discuss how AI, virtual care, and remote monitoring are reshaping orthopedic practice. He also shares insights on emerging innovations in sports medicine, wearable technology, and the evolving role of biologics in patient care.

In this episode, Frank A. Cordasco, MD, MS, Professor of Orthopaedic Surgery at Weill Cornell Medical College and Attending Surgeon at the Hospital for Special Surgery, joins the Becker's Spine and Orthopedics Podcast to discuss how AI, virtual care, and remote monitoring are reshaping orthopedic practice. He also shares insights on emerging innovations in sports medicine, wearable technology, and the evolving role of biologics in patient care.

In this episode, Frank A. Cordasco, MD, MS, Professor of Orthopaedic Surgery at Weill Cornell Medical College and Attending Surgeon at the Hospital for Special Surgery, joins the Becker's Spine and Orthopedics Podcast to discuss how AI, virtual care, and remote monitoring are reshaping orthopedic practice. He also shares insights on emerging innovations in sports medicine, wearable technology, and the evolving role of biologics in patient care.

In our January episode, we focused on our Healthy Now, Healthy Later philosophy with the Benefit Funds' Deputy Chief Medical Officer Dr. Lela Mayers. Dr. Mayers shared how prioritizing your health now can help you lower your risk of illness and improve your quality of life later. For our January Key Note, Dr. Mayers walks us through what to expect during a typical wellness checkup—and explains why it's so important to make that appointment. The Takeaway We want to hear from you! Please complete our survey: org/member-feedback. Drop us a line at our social media channels: Facebook// Instagram // YouTube. Start—or renew!—your health journey by making an appointment with your primary care physician. Visit our Provider Directory at 1199SEIUBenefits.org/find-a-provider. Know your numbers to find out where you stand: 1199SEIUBenefits.org/healthyhearts. Visit our Healthy Living Resource Center for wellness tips, information and resources; 1199SEIUBenefits.org/healthyliving. Talk to your doctor about any screenings you may need: 1199SEIUBenefits.org/healthybodies. Connect with a primary care doctor or a therapist online through Teladoc: Teladoc.com or (800) TELADOC (835-2362). Need support managing your diabetes, hypertension or weight? Find the program that's right for you: 1199SEIUBenefits.org/the-choice-is-yours/ Find a mental health therapist through the Benefit Funds' Provider Directory: 1199SEIUBenefits.org/find-a-provider. For additional support, call our Wellness Member Assistance Program: (646) 473-6900. Contact our partners at the National Alliance on Mental Illness (NAMI) for a wide variety of community resources: naminycmetro.org. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to view webinars on managing stress, building healthy meals and more: www.1199SEIUBenefits.org/videos. Visit our YouTube Channel to view a wide collection of healthy living videos: youtube.com/@1199SEIUBenefitFunds/playlists Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents Guest Bio Dr. Lela Mayers is the Deputy Chief Medical Officer (DCMO) of the 1199SEIU Benefit Funds, which provide comprehensive self-insured, self-administered healthcare benefits to more than 450,000 healthcare workers, retirees and their families. As DCMO, Dr. Mayers assists the Chief Medical Officer with the Benefit Funds' clinical and care management strategies, as well as health and wellness initiatives. Prior to joining the Benefit Funds, Dr. Mayers served as Senior Medical Director at CVS Health/Aetna. There she collaborated with the account management teams, pharmacy teams, consulting firms and plan sponsors to drive improved health outcomes for commercial and labor health plan members. Prior to that, she served as Chief of Medicine at Premier Healthcare, where she managed five ambulatory health centers across New York City. Her previous experience with union membership was earned at the Benefit Fund of the New York Hotel Trades, where she was medical director of the Harlem Health Center. Dr. Mayers worked for many years as a primary care physician at the Farrell Health Center of NewYork-Presbyterian Hospital, where she served as faculty and medical director of the resident training program. Dr. Mayers continues to hold a position as voluntary faculty/instructor in clinical medicine at Columbia University's Center for Family and Community Medicine. She is a licensed physician in New York State and is board certified with the American Board of Family Medicine. Dr. Mayers received a Bachelor of Arts from Cornell University, a Doctor of Medicine from Cornell University Medical College (now Weill Cornell Medical College) and a Master of Public Health from the Mailman School of Public Health at Columbia University.

Why do so many healthcare providers still view obesity as a lifestyle choice rather than a complex chronic disease—and how can we change that?In this Echo Episode, Dr. Andrea Austin interviews Dr. Katherine Saunders about her journey from pre-med influences to pioneering obesity medicine at Weill Cornell and co-founding FlyteHealth. They explore obesity's scientific underpinnings, the impact of weight bias, practical advice for EM physicians in brief encounters, common weight-promoting medications, the value of bariatric surgery, and emerging tools like genetic testing and AI-driven algorithms. Katherine emphasizes empathy, permission-based discussions, and multidisciplinary approaches to treat obesity as the root cause of over 200 comorbidities.You'll hear how they:Debunk obesity myths perpetuated in medicine, framing it as a chronic disease requiring medical intervention beyond "eat less, exercise more"Provide strategies for EM docs to discuss weight compassionately in 5 minutes, including asking permission, using neutral language, and offering resources without judgmentDiscuss weight-promoting factors like medications (e.g., progesterone-focused birth control), stress, genetics, and sleep apnea, plus the role of bariatric surgery and anti-obesity medsHighlight innovative obesity care through FlyteHealth's telehealth platform, AI algorithms for personalized treatment, and collaborative post-surgical managementIf you're a physician encountering obesity-related issues in acute care or seeking better ways to support patients, this episode delivers empathetic insights and actionable tools for transformative care.About the Guest:"Obesity isn't just a lifestyle problem, it's a complex chronic disease we can now treat effectively." – Dr. Katherine SaundersDr. Katherine Saunders, MD, FTOS is a leading obesity medicine expert, co-founder and executive vice president of FlyteHealth, and clinical assistant professor at Weill Cornell Medicine. She received her undergraduate degree Phi Beta Kappa/Summa Cum Laude from Dartmouth College and her medical degree from Weill Cornell Medical College, where she became a member of the Alpha Omega Alpha Honor Medical Society.  She completed her residency at New York-Presbyterian and was the first obesity medicine fellow at Weill Cornell's Comprehensive Weight Control Center. Board-certified in internal medicine and obesity medicine, she hosts the Weight Matters podcast, speaks internationally, and has been recognized as a top influencer in wellness.

SPECIAL: Where Pain, Fitness and Performance Meet Vol.3 How Your Anatomy and Structure Impacts Rehab Programming with Dr. Kathy Dooley Bio: Dr. Dooley is a chiropractor, practicing in midtown Manhattan and Denver and Boulder, CO. Dr. Dooley is an anatomy instructor at two New York City medical schools, Albert Einstein College of Medicine and Weill Cornell Medical College. She is also an adjunct instructor at New York University's College of Dentistry and a visiting professor for Saint George's University Medical School in Grenada, West Indies. She is also the founder of Immaculate Dissection and a lead instructor for the seminar series, NeuroKinetic Therapy and for Somatic Senses Education. She writes for her own website, drdooleynoted.com. She is also former reviewer for the scientific journal Clinical Anatomy Links: https://drdooleynoted.com www.immaculatedissection.com @immaculatedissection on Instagram Email: drkathydooley@gmail.com — Get your FREE eBook and Webinar at www.foreverclientformula.com The Principles of Performance is proud to be recognized by FeedSpot as one of the Top 30 Fitness Podcasts: https://podcast.feedspot.com/fitness_podcasts/ We have also been recognized as one of the Top 100 Strength Coach Podcasts on the web by MillionPodcasts: https://www.millionpodcasts.com/strength-coach-podcasts/

Happy New Year, and welcome to Season Three of Health Is the Key. With the holidays behind us, we turn our focus to the year ahead of us – a perfect time to re-commit to our health. And what better way to introduce our new Healthy Now, Healthy Later campaign than to have the Benefit Funds' Deputy Chief Medical Officer Dr. Lela Mayers as our first guest in 2026! Dr. Mayers explains how preventive care can lower your risk of illness, improve your quality of life and help ensure long-term wellness. She also explores with us all the resources available to you to support you wherever you are on your health journey. The Takeaway We want to hear from you! Please complete our survey: org/member-feedback. Drop us a line at our social media channels: Facebook// Instagram // YouTube. Start – or renew! – your health journey by making an appointment with your primary care physician. Visit our Provider Directory at 1199SEIUBenefits.org/find-a-provider. Know your numbers to find out where you stand: 1199SEIUBenefits.org/healthyhearts. Visit our Healthy Living Resource Center for wellness tips, information and resources; 1199SEIUBenefits.org/healthyliving. Talk to your doctor about any screenings you may need: 1199SEIUBenefits.org/healthybodies. Connect with a primary care doctor or a therapist online through Teladoc: Teladoc.com or (800) TELADOC (835-2362). Need support managing your diabetes, hypertension or weight? Find the program that's right for you: 1199SEIUBenefits.org/the-choice-is-yours/ Find a mental health therapist through the Benefit Funds' Provider Directory: 1199SEIUBenefits.org/find-a-provider. For additional support, call our Wellness Member Assistance Program: (646) 473-6900. Contact our partners at the National Alliance on Mental Illness (NAMI) for a wide variety of community resources: naminycmetro.org. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to view webinars on managing stress, building healthy meals and more: www.1199SEIUBenefits.org/videos. Visit our YouTube Channel to view a wide collection of healthy living videos: youtube.com/@1199SEIUBenefitFunds/playlists Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents. Guest Bio Dr. Lela Mayers is the Deputy Chief Medical Officer (DCMO) of the 1199SEIU Benefit Funds, which provide comprehensive self-insured, self-administered healthcare benefits to more than 450,000 healthcare workers, retirees and their families. As DCMO, Dr. Mayers assists the Chief Medical Officer with the Benefit Funds' clinical and care management strategies, as well as health and wellness initiatives. Prior to joining the Benefit Funds, Dr. Mayers served as Senior Medical Director at CVS Health/Aetna. There she collaborated with the account management teams, pharmacy teams, consulting firms and plan sponsors to drive improved health outcomes for commercial and labor health plan members. Prior to that, she served as Chief of Medicine at Premier Healthcare, where she managed five ambulatory health centers across New York City. Her previous experience with union membership was earned at the Benefit Fund of the New York Hotel Trades, where she was medical director of the Harlem Health Center. Dr. Mayers worked for many years as a primary care physician at the Farrell Health Center of NewYork-Presbyterian Hospital, where she served as faculty and medical director of the resident training program. Dr. Mayers continues to hold a position as voluntary faculty/instructor in clinical medicine at Columbia University's Center for Family and Community Medicine. She is a licensed physician in New York State and is board certified with the American Board of Family Medicine. Dr. Mayers received a Bachelor of Arts from Cornell University, a Doctor of Medicine from Cornell University Medical College (now Weill Cornell Medical College) and a Master of Public Health from the Mailman School of Public Health at Columbia University.

In this episode, I sit down with Dr. Lisa Mosconi, director of the Women's Brain Initiative at Weill Cornell Medical College, to challenge one of the most deeply ingrained assumptions in brain health: that Alzheimer's is largely out of our control.If you've ever felt like Alzheimer's risk is something you can only react to later in life, this conversation may completely change how you think about your brain—and what you can do to protect it now.For full show notes and transcript: https://drgundry.com/lisa-mosconi-alzheimers-preventionThank you to our sponsors! Check them out: Get a quote today at Progressive.com.Transform your sleep experience with Cozy Earth bedding. Go to cozyearth.com/gundry for 40% off.For all your blue-light and EMF-blocking accessories, go to boncharge.com/GUNDRY and use the coupon code GUNDRY to save 25% off your entire order. Get convenient, high-quality, and affordable groceries delivered with Thrive Market. Get $80 in free groceries at thrivemarket.com/gundrypodcast.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The human heart is a tireless biomechanical marvel—an exquisitely engineered pump powered by both mechanical precision and an intrinsic electrical system, beating over 100,000 times a day to sustain life. But like any machine, despite having an electrical mind of its own, it is not infallible—when its rhythm drifts or its mechanics strain, the impact is felt far beyond the chest. From more complex cases like heart failure and detrimental arrhythmias to the more-known feared heart attack caused by high cholesterol, it leads to questions — What can we do to safeguard the health of our heart? What should one do when they experience chest pain? And how do we learn to listen to the heart's warning signs before they become life-altering events?In this episode, we are joined by Dr. Diala Steitieh, MD, a board-certified cardiologist and assistant professor of clinical medicine, focusing on hypertrophic cardiomyopathy and sports cardiology, based in New York City.Dr. Steitieh received her MD from Weill Cornell Medicine in Qatar and completed her Internal Medicine Residency and Cardiovascular Disease Fellowship at NewYork-Presbyterian Hospital/Weill Cornell Medical College. Currently, Dr. Steitieh serves as an Assistant Professor of Clinical Medicine and Principal Investigator of clinical studies at Weill Cornell Medical College and the Director of the Hypertrophic Cardiomyopathy Program in the Division of Cardiology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.Dr. Steitieh has been featured on Yahoo!, SELF Magazine, Qatar Tribune, MSN, TCTMD, and The Peninsula Qatar.Follow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz (Host): Instagram, YouTube

If you're enjoying the content, please like, subscribe, and comment! Dr. Schwartz's Links: Website: https://www.theodorehschwartzmd.com/ Book: https://www.penguinrandomhouse.com/books/734286/gray-matters-by-theodore-h-schwartz/ Theodore H. Schwartz, MD graduated Magna Cum Laude in Philosophy and English from Harvard University and Magna Cum Laude in Neuroscience from Harvard Medical School. After completing his residency and chief residency in Neurosurgery at The Neurological Institute of New York at Columbia-Presbyterian Medical Center, Dr. Schwartz spent a year at Yale-New Haven Medical Center where he received advanced fellowship training in epilepsy and brain tumor surgery. He completed a post-doctoral fellowship at the Max Planck Institute in Munich, Germany funded by the Van Wagenen Fellowship and the Von Humboldt Society. Dr. Schwartz spent 25 years as a Professor of Neurosurgery, Otolaryngology, and Neuroscience at Weill Cornell Medical College, New York Presbyterian Hospital. Samir's Links: https://samirvarma.com/ https://www.substack.com/@samirvarma Samir is an Author, Physicist, Entrepreneur, Inventor, and Hedge Fund Manager. He has a PhD in Theoretical Physics from The University of Texas. The incomparable E.C.G. Sudarshan was his advisor and Nobelist Steven Weinberg was on his dissertation committee. He is the author of The Physics of Free Will: How Determinism Affects Everything from The Future of AI to Traffic to God to Bees. He is working on a second book tentatively titled, I Wish I Had Known That about economics, finance and politics. ______________________ Follow us! @worldxppodcast Instagram - https://bit.ly/3eoBwyr @worldxppodcast Twitter - https://bit.ly/2Oa7Bzm YouTube - http://bit.ly/3rxDvUL Spotify - http://spoti.fi/3sZAUTG #god #religion #free #freewill #determination #christian #ai #physics #law #neuroscience #neurosurgery #subscribe #explore #explorepage #podcastshow #longformpodcast #longformpodcast #podcasts #podcaster #newpodcast #podcastshow #podcasting #newshow #worldxppodcast #viralvideo #youtube

From microplastics and “forever chemicals” in household items—from our kitchens to our bathrooms—to the charred bits of meat on a barbecue grill, to the smoke and fumes we inhale simply by walking through a city, and recently even kimchi (?!), concern about cancer risk seems to be everywhere. Like cancer metastasis itself, the conversation is rapidly spreading across social media and online forums. But how many of these so-called “carcinogens” are truly worth our time, apprehension, and caution?In this episode, we are joined by Dr. Timothy Tiutan, MD (known online as Dr. Tim), a board-certified internal medicine physician, oncology/cancer hospitalist, author of 'The Mediterranean Diet,' and assistant medical professor based in New York City. With nearly two million followers on social media, Dr. Tiutan's unique "edutainment" style delivers pertinent general health and cancer-prevention education to his online audience.Dr. Tiutan received his BA/BS in Spanish and Physiology and MD from the University of Arizona College of Medicine and completed his Internal Medicine residency at Weill Cornell Medical College. Currently, he is an oncology specialist at Memorial Sloan Kettering Cancer Center, Medical Contributor at CBS News, the official media spokesperson of the American Cancer Society, and a member of the World Health Organization (WHO) Fides Network, a select group from around the world that combats misinformation in the media and supports health initiatives for communities globally.Dr. Tiutan has been featured on the New York Post, HuffPost, Yahoo!, Daily Record, UNILAD, LADBible, The Independent, Times of India, CBS News, and Daily Mail.Follow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz (Host): Instagram, YouTube

In this episode, Anthony J. Tortolani, MD, FACS, FACC, Cardiac and Thoracic Surgeon and Professor Emeritus of Clinical Cardiothoracic Surgery at Weill Cornell Medical College, discusses the realities of declining profit margins and how leaders are balancing financial pressures with clinical excellence. He explores practical applications of AI in clinical medicine, including improvements in efficiency and less invasive surgical approaches, and shares why aligning strategic vision with day-to-day tactical planning is essential for long-term success in cardiovascular care.

In this episode, Anthony J. Tortolani, MD, FACS, FACC, Cardiac and Thoracic Surgeon and Professor Emeritus of Clinical Cardiothoracic Surgery at Weill Cornell Medical College, discusses the realities of declining profit margins and how leaders are balancing financial pressures with clinical excellence. He explores practical applications of AI in clinical medicine, including improvements in efficiency and less invasive surgical approaches, and shares why aligning strategic vision with day-to-day tactical planning is essential for long-term success in cardiovascular care.

In this episode, Anthony J. Tortolani, MD, FACS, FACC, Cardiac and Thoracic Surgeon and Professor Emeritus of Clinical Cardiothoracic Surgery at Weill Cornell Medical College, discusses the realities of declining profit margins and how leaders are balancing financial pressures with clinical excellence. He explores practical applications of AI in clinical medicine, including improvements in efficiency and less invasive surgical approaches, and shares why aligning strategic vision with day-to-day tactical planning is essential for long-term success in cardiovascular care.

PART 2I n this episode, we're joined by Dr. Andrew Zhang, and we explore Lumbar Interbody fusion. We discuss indications, relevant anatomy, differences between ALIF, OLIF, XLIF, + much much more.   Dr. Zhang is a board-certified, dual fellowship-trained orthopaedic surgeon specializing in spine surgery. He has a clinical interest in treating complex spinal deformity in adult and pediatric patients, including scoliosis and kyphosis, as well as robotic surgery, minimally invasive techniques, and the latest technology such as endoscopic spine surgery. His patient-centered approach involves empowering patients by educating them on their individual spinal conditions and developing a specific evidence-based treatment plan together with them as if they were his own family members. Dr. Zhang also has a particular interest in teaching residents and medical students and is actively involved in several research studies. He has been published in numerous peer-reviewed scientific journals and textbooks, and he has presented posters and on podiums at several national and international conferences. Dr. Zhang earned dual undergraduate degrees in biology and economics with highest honors from The George Washington University and obtained his medical degree with distinction in research from the same institution. He completed his orthopaedic surgery residency at Louisiana State University. He then completed an advanced spine fellowship at Brown University, followed by additional spine training at Yale University and the Shriners Hospitals for Children in Philadelphia and Shreveport. Dr. Zhang completed a second fellowship in advanced adult and pediatric comprehensive spine surgery at New York-Presbyterian/Columbia University/Cornell University, training with the world's foremost experts in spine surgery. He served as an Assistant Attending and Postdoctoral Clinical Fellow at Columbia University's Vagelos College of Physicians and Surgeons as well as a Clinical Instructor of Orthopedic Surgery in Neurological Surgery at Weill Cornell Medical College. His higher education culminated in graduating with distinction from the Surgical Leadership Program at Harvard University. Prior to joining Penn Medicine, Dr. Zhang was the Chief of Adult and Pediatric Orthopaedic Spine Surgery, as well as an Assistant Professor and the Associate Program Director to the Orthopaedic Surgery Residency at Louisiana State University Health Sciences Center. Education and training Medical School: George Washington University Residency: Montefiore Medical Center Residency: Louisiana State University Hospital Fellowship: Brown University Fellowship: NewYork-Presbyterian/Columbia University Medical Center Fellowship: Harvard University Goal of episode: To develop a baseline knowledge of Lumbar Interbody Fusion In this episode, we cover a wide array of topics including: Lumbar interbody fusion vs posterolateral fusion indications for interbody fusion danger and surgical pearls for ALIF, OLIF, XLIF, PLIF pertininent lumbar spine surgical anatomy 

Prosthetic joint infections (PJI) remain among the most devastating complications in orthopedic surgery, with increasing incidence paralleling the growth in arthroplasty procedures worldwide. While treatment protocols are well-established, evidence supporting current approaches is lacking, and outcomes remain suboptimal, highlighting the need for improved therapeutic strategies. AAC recently published a minireview of randomized controlled trials and emerging evidence for the management for these difficult to treat infection. Today, we discuss with one of the authors of the manuscript and an ID doctor specialized in PJI infections the findings of such paper. Topics discussed: Challenges of treating prosthetic joint infections. Major clinical trial data supporting different approaches for treatment and prevention of PJI Guidance for the approach to these complicated infections. Guests: David Paterson MBBS, Ph.D., Professor, Saw Swee Hock School of Public Health (Joint) Yong Loo Lin School of Public Health (Joint), Director, ADVANCE-ID, National University of Singapore, Singapore.  Ana Victoria Salas-Vargas, M.D. Assistant Professor of Clinical Medicine, Houston Methodist Academic Institute and Weill Cornell Medical College.  This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.  Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

In this episode, we're joined by Dr. Andrew Zhang, and we explore Lumbar Interbody fusion. We discuss indications, relevant anatomy, differences between ALIF, OLIF, XLIF, + much much more.   Dr. Zhang is a board-certified, dual fellowship-trained orthopaedic surgeon specializing in spine surgery. He has a clinical interest in treating complex spinal deformity in adult and pediatric patients, including scoliosis and kyphosis, as well as robotic surgery, minimally invasive techniques, and the latest technology such as endoscopic spine surgery. His patient-centered approach involves empowering patients by educating them on their individual spinal conditions and developing a specific evidence-based treatment plan together with them as if they were his own family members. Dr. Zhang also has a particular interest in teaching residents and medical students and is actively involved in several research studies. He has been published in numerous peer-reviewed scientific journals and textbooks, and he has presented posters and on podiums at several national and international conferences. Dr. Zhang earned dual undergraduate degrees in biology and economics with highest honors from The George Washington University and obtained his medical degree with distinction in research from the same institution. He completed his orthopaedic surgery residency at Louisiana State University. He then completed an advanced spine fellowship at Brown University, followed by additional spine training at Yale University and the Shriners Hospitals for Children in Philadelphia and Shreveport. Dr. Zhang completed a second fellowship in advanced adult and pediatric comprehensive spine surgery at New York-Presbyterian/Columbia University/Cornell University, training with the world's foremost experts in spine surgery. He served as an Assistant Attending and Postdoctoral Clinical Fellow at Columbia University's Vagelos College of Physicians and Surgeons as well as a Clinical Instructor of Orthopedic Surgery in Neurological Surgery at Weill Cornell Medical College. His higher education culminated in graduating with distinction from the Surgical Leadership Program at Harvard University. Prior to joining Penn Medicine, Dr. Zhang was the Chief of Adult and Pediatric Orthopaedic Spine Surgery, as well as an Assistant Professor and the Associate Program Director to the Orthopaedic Surgery Residency at Louisiana State University Health Sciences Center. Education and training Medical School: George Washington University Residency: Montefiore Medical Center Residency: Louisiana State University Hospital Fellowship: Brown University Fellowship: NewYork-Presbyterian/Columbia University Medical Center Fellowship: Harvard University Goal of episode: To develop a baseline knowledge of Lumbar Interbody Fusion In this episode, we cover a wide array of topics including: Lumbar interbody fusion vs posterolateral fusion indications for interbody fusion danger and surgical pearls for ALIF, OLIF, XLIF, PLIF pertininent lumbar spine surgical anatomy 

Send us a textAfter birth, many women are left blindsided by physical changes they never expected. Vaginal dryness, painful sex, recurring UTIs, and even emotional strain can all show up during breastfeeding — but most mothers are never told why. In this episode, we sit down with Sara Perelmuter, a third-year medical student at Weill Cornell Medical College in New York City. Sara currently serves as president of the Sexual Medicine Research Team and has authored numerous peer-reviewed publications on reproductive and genitourinary health.Sara explains the hormonal shifts that mimic menopause in the postpartum period, why so many women are suffering in silence, and what the research reveals about both the prevalence of these symptoms and the safe, effective treatments available — including pelvic floor therapy, moisturizers, lubricants, and topical vaginal estrogen.These symptoms are common, but they are not inevitable. By naming and studying them, we open the door to treatment and better care.********** Needed

Physician and New Yorker writer Dhruv Khullar says artificial intelligence is a powerful tool to get quicker and more accurate diagnoses. But it can also be dangerous.Guest:Dhruv Khullar, Physician, Weill Cornell Medical College; Contributing Writer, The New YorkerWe want to hear from you! Our audience survey takes less than ten minutes, and you'll be entered to win one of two $50 Bookshop.org gift cards.Learn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

The More Sibyl Podcast Presents: 암 너머의 인간| The One with Dr. Andrew Roth — Men, Medicine, and Meaning: The Emotional Landscape of Prostate Cancer| Episode 31 (2025)What does it mean to live well, even in the face of illness? How do we care for those navigating both the physical and emotional realities of cancer?In this episode of The More Sibyl Podcast, we sit down with one of the pioneers of psycho-oncology, Dr. Andrew Roth, Professor Emeritus of Clinical Psychiatry at Weill Cornell Medical College and longtime attending psychiatrist at Memorial Sloan Kettering Cancer Center.Together, we explore the emotional ripple effects of a cancer diagnosis, how anxiety and shame often hide beneath stoicism, and why naming our fears can sometimes be the most courageous act of all. Dr. Roth introduces tools like the Distress Thermometer and MAX-PC (Memorial Anxiety Scale for Prostate Cancer), simple yet profound ways clinicians can detect emotional suffering early, before it turns into isolation. These tools, he explains, aren't just checklists; they're bridges that reconnect patients to language, to care, and to hope.But perhaps the most powerful insight from Dr. Roth is this: healing doesn't always mean cure. Sometimes it means learning how to live with uncertainty, reclaiming joy in moments that medicine can't measure, and building relationships that remind us we are more than our diagnosis.He speaks of the courage it takes for men to open up, for partners to listen without judgment, and for doctors to lead with empathy rather than ego. In sharing his own journey, from community organizing in Brooklyn to a lifetime of helping patients find meaning in the midst of uncertainty, Dr. Roth shows how emotional honesty can transform medical care and what it truly means to “live better” with illness.Whether you're a clinician, caregiver, patient, or loved one walking beside someone in pain, this conversation will leave you with a renewed understanding of how connection, courage, and curiosity can shape the way we heal and the way we live.Because healing, as Dr. Roth reminds us, isn't just medical. It's profoundly human.

Description: Listen as NPF Medical Board Members, dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman discuss the connections between psoriasis and psoriatic arthritis, from cytokines to triggers, current and future treatments.   Join moderator Alan Simmons as he gains insights on what connects psoriasis and psoriatic arthritis with leading experts in psoriatic disease and NPF Medical Board members, dermatologist Dr. Robert Kalb with Buffalo Medical Group Dermatology, and rheumatologist Dr. Sergio Schwartzman from Schwartzman Rheumatology, as they discuss the known drivers of psoriasis and psoriatic arthritis, common triggers, benefits of targeted treatments, remission of disease, and upcoming treatment trends. The intent of this episode is to identify potential connections between psoriasis and psoriatic arthritis, and how targeted treatments have changed the outlook for management of psoriatic disease. This episode is sponsored by Novartis. Timestamps: (0:41) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman who are both involved in clinical care and research of psoriasis and psoriatic arthritis.  (1:15) Current known pro-inflammatory cytokines and cells found in psoriasis and psoriatic arthritis.   (5:33) Types of psoriasis that may lead to a higher risk of developing psoriatic arthritis. (9:33) Common triggers for psoriasis and psoriatic arthritis that could cause flares of the disease. (12:59) Key factors that are considered when choosing a treatment plan for any individual with psoriatic arthritis and psoriasis. (18:04) What treatment remission means for psoriasis. (19:36) Use of minimal disease activity (MDA) in psoriatic arthritis and what it means. (22:14) How a better understanding of the disease has led to more effective treatment choices and what choices are used by Dr. Kalb and Dr. Schwartzman for the management of psoriasis and psoriatic arthritis. (28:39) New developments in treatment and research in psoriatic arthritis and psoriasis. (36:01) Given treatment advancements it's a wonderful time to treat psoriatic disease. 3 Key Takeaways: ·       Cytokines are chemicals in the body that moderate various processes. In psoriasis and psoriatic arthritis,  an unknown trigger stimulates some cells to overproduce pro-inflammatory cytokines such as TNF-alpha, IL-17 or IL-23 leading to the development of skin and joint disease.  ·       Treating psoriasis and psoriatic arthritis helps move the body towards normalizing the over reactive immune system especially with more targeted treatments that safely and effectively block specific cytokines without affecting other organ systems.  ·       Given advancements in targeted treatments the goal is to reach and maintain remission of psoriatic disease. Guest Bios:   Leading dermatologist Robert Kalb, M.D. is the Chair of the Buffalo Medical Group Dermatology Department and the Director of the Buffalo Medical Group Phototherapy Center, one of the leading centers for psoriasis care in Western New York. He is also a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences (SUNY Buffalo), as well as an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania where he plays a significant role in medical education, mentoring both medical students and dermatology residents. Dr. Kalb has extensive experience managing psoriasis, atopic dermatitis, and other inflammatory skin diseases. He has authored 70+ publications and is actively involved in clinical research, particularly focused on new treatment options for psoriasis. He is a member of the NPF Medical Board, American Academy of Dermatology, and is a member of the International Psoriasis Council.  Sergio Schwartzman, MD, is a world-renowned rheumatologist based in New York City who brings almost 40 years of experience and personalized clinical care for those who have psoriatic disease. Along with being in private practice at Schwartzman Rheumatology, Dr. Schwartzman is a Clinical Associate Professor of Medicine at Weill Cornell Medical College of Cornell University, the New York-Presbyterian Hospital, and the Hospital for Special Surgery in New York City where he has played a role in educating medical students, residents, fellows, and peers in rheumatology. Additionally, Dr. Schwartzman is the emeritus Franchellie M. Cadwell Clinical Associate Professor at the Hospital for Special Surgery. Dr. Schwartzman's current research interests include psoriatic arthritis, the spondyloarthritis group of diseases, ankylosing spondylitis, rheumatoid arthritis, as well as defining and treating autoimmune diseases of the eye. He has authored, co-authored, and edited over 150 papers, abstracts, books and book chapters on topics including psoriatic arthritis, ankylosing spondylitis, axial spondylarthritis, rheumatoid arthritis, lupus, autoimmune eye disorders, and other rheumatological and autoimmune conditions. He is a member of the NPF Medical Board. He is also a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Resources: Ø  “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025.   Ø  Treatment and Management of Psoriasis     Ø  Treatment and Management of Psoriatic Arthritis  

If you're enjoying the content, please like, subscribe, and comment! Dr. Schwartz's Links: Website: https://www.theodorehschwartzmd.com/ Book: https://www.penguinrandomhouse.com/books/734286/gray-matters-by-theodore-h-schwartz/ Theodore H. Schwartz, MD graduated Magna Cum Laude in Philosophy and English from Harvard University and Magna Cum Laude in Neuroscience from Harvard Medical School. After completing his residency and chief residency in Neurosurgery at The Neurological Institute of New York at Columbia-Presbyterian Medical Center, Dr. Schwartz spent a year at Yale-New Haven Medical Center where he received advanced fellowship training in epilepsy and brain tumor surgery. He completed a post-doctoral fellowship at the Max Planck Institute in Munich, Germany funded by the Van Wagenen Fellowship and the Von Humboldt Society. Dr. Schwartz spent 25 years as a Professor of Neurosurgery, Otolaryngology, and Neuroscience at Weill Cornell Medical College, New York Presbyterian Hospital. He was named David and Ursel Barnes Professor in Minimally Invasive Surgery, the first endowed professorship in the department, Vice-Chairman of Clinical Research, the Director of Anterior Skull Base and Pituitary Surgery, Co-Director of Surgical Neuro-Oncology, the Director of Epilepsy Surgery, and ran a basic science laboratory investigating the causes and treatment for epilepsy. He has received K08, R01 and R21 funding from the NINDS for his research and has served on several NIH review committees.Dr. Schwartz's book Gray Matters: A Biography of Brain Surgery, published by Dutton/Penguin-Random House, was selected by The Economist as one of the best books of 2024. His nonfiction writing has been featured in the Wall Steet Journal, the Boston Globe, Psyche Magazine, and The Psychologist. Dr. Schwartz is currently the Founder and CEO of a med tech device company called illumination Diagnostics._______________________Follow us!@worldxppodcast Instagram - https://bit.ly/3eoBwyr@worldxppodcast Twitter - https://bit.ly/2Oa7BzmSpotify - http://spoti.fi/3sZAUTGYouTube - http://bit.ly/3rxDvUL#neuroscience #surgeon #medschool #medical #neurosurgeon #surgery #medicine #medicalstudent #cte #tbi #trauma #traumaticbraininjury #concussion #subscribe #explore #explorepage #podcastshow #longformpodcast #podcasts #podcaster #podcasting #worldxppodcast #viralvideo #youtubeshorts

This week on Health Matters, Courtney talks with nutritionist Gabrielle Gambino and Dr. Jonathan Waitman about the role that sweeteners play in our diet, and how certain options like high fructose corn syrup and cane sugar impact our health. ___Dr. Jonathan Waitman is board certified in Internal Medicine and Clinical Nutrition. He is the course director for the nutrition curriculum and Weill Cornell Medical College. He is also the Medical Director for Specialized Nutrition Support New York Presbyterian Hospital, Weill-Cornell Medical Center. Following completion of his training in Internal Medicine he then went to Memorial Sloan Kettering Cancer Center where he completed a fellowship in clinical nutrition. He has co-authored numerous articles on the subject of obesity. Gabrielle Gambino, MS, RD, CDN, CNSC has undergraduate degrees in Clinical Nutrition and Public Relations from Penn State University. She later went on to complete her Master's in Clinical Nutrition at New York University, and obtained her specialty certification as a Certified Nutrition Support Clinician (CNSC). Gabrielle specializes in nutrition care for patients with advanced heart failure and enjoys finding novel ways to optimize patients' nutritional status before advanced therapies.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's episode is going to focus on the management of rotator cuff retears — including tips and tricks for successful revision repair and augmentation options.We are joined today by two outstanding guests! Dr. Brian Waterman is a Professor of orthopedic surgery at Wake Forest University School of Medicine, Chief of Sports Medicine & Shoulder Surgery at Wake Forest Baptist Medical Center and Director of the Sports Medicine & Shoulder Surgery Fellowship. He is on the editorial board of the Arthroscopy Journal and American Journal of Orthopaedics. Dr. Waterman is a team physician for Wake Forest University, Winston-Salem Dash and US Ski and Snowboard.Dr. Gabriella Ode is an orthopedic surgeon specializing in sports medicine and shoulder surgery at the Hospital for Special Surgery, Assistant Professor of orthopedic surgery at Weill Cornell Medical College and adjunct faculty with the Department of Bioengineering at Clemson University. She is also a team orthopaedic surgeon for the New York Liberty of the WNBA.So, without further ado, let's get to the Exhibit Hall!

Behind every surgeon's mask is a story you'd never expect—like navigating residency during a divorce, surviving cancer, and still finding time to write books that inspire the next generation.   In this episode, Dr. Tali Lando, a pediatric ENT surgeon, shares her deeply personal and professional journey—from being the only doctor in a large Jewish family to surviving a grueling residency during a divorce, experiencing a miscarriage during fellowship, and ultimately thriving as a surgeon, mother of three, and published author. She candidly discusses the challenges of balancing her demanding career with motherhood, the chaos behind the polished image, and how she carved out time to write two impactful books, including her latest, Breathless: Surgical Tales from the Brink and Back. Through stories both heart-wrenching and humorous, Dr. Lando reflects on resilience, the unpredictability of medicine, and the power of narrative to heal, teach, and inspire.   Tune in to hear a powerful, unfiltered conversation that will leave you inspired, moved, and reminded of the strength it takes to heal others while healing yourself.   Episode Highlights: ●      About Dr. Tali Lando ●      How her childhood fascination with neonatology evolved into a career in Pediatric Ear, Nose and Throat Surgeon ●      Overcoming her personal hardships ●      Juggling a demanding surgical career with the chaos of family life ●      Her path to becoming an author and the process of writing her books ●      Stories from her first book, “Hell and Back” ●      Insights from her new book, Breathless: Surgical Tales from the Brink and Back ●      Her dreams of reaching medical students, creating an audiobook, and adapting her work into a TV series ●      The importance of storytelling, resilience, and finding purpose in the most difficult moments   About Dr. Tali Lando: Dr. Tali Lando is a pediatric otolaryngologist, author, speaker, and breast cancer survivor whose compelling voice bridges the worlds of medicine and memoir. Fellowship-trained at the Children's Hospital of Philadelphia and a graduate of the Cornell-Columbia ENT residency program, Dr. Lando holds honors from Weill Cornell Medical College and graduated summa cum laude in neuroscience from Columbia University. Her debut memoir, Hell and Back: Doctor and Patient, Wife and Mom, Dragon Slayer, has been widely acclaimed for its raw honesty and fierce humor. Her second book, “Breathless: Surgical Tales from the Brink and Back” is now available for pre-order on amazon. Her voice is real, raw, full, and heartfelt. Her writing is enthralling, superb, and unflinchingly honest—an edge-of-your-seat experience that resonates deeply with readers. Her stories are vivid and complex, with evolving storylines that unfold like episodes from a gripping, high-stakes medical drama. A frequent guest on podcasts and in online media, Dr. Lando also connects with a wide audience through her Instagram videos, which are a hit with followers for their wit, insight, and authenticity. A former New York City girl and now a mother of three daughters in Westchester, she brings authenticity, medical insight, and humanity to every stage she steps on and every story she tells.  Her upcoming book, Breathless (releasing this fall), offers an edge-of-your seat, gripping, deeply human look into the world of pediatric  surgery. “A testament to the precision, resilience, and compassion that define the very best of medicine… A must-read for anyone entering the world of medicine or seeking purpose in their surgical journey.” Dr. Lando continues to inspire with her candor, compassion, and unwavering commitment to both her patients and the next generation of physicians.  To Pre-Order Breathless: Surgical Tales from the Brink (and Back): https://www.amazon.com/Breathless-Surgical-Tales-Brink-Back/dp/1948238535/   Connect with Dr. Tali Lando: ●      Website | drtalilando.com ●      Linked In | www.linkedin.com/in/tali-lando ●      Instagram | @drtalilando

Dr. Flora Waples, a board-certified physician, received double majors in Chemistry and Biochemistry from the University of Chicago in 2000 and graduated from Cornell Medical School at Weill Cornell Medical College in New York City in 2006. After receiving her MD from this Ivy League institution, she completed her residency in Emergency Medicine and Trauma care at the University of Chicago—a training program consistently ranked among the top three in the nation. Dr. Waples began to study and perform aesthetic procedures in 2010 – and in 2011, she founded RESTOR with her sister Dominique. Together – they have grown RESTOR from a single location with one provider into a regionally known center of excellence with three locations and counting. Dr. Waples has always had the dream of growing RESTOR into a complete wellness and aesthetics practice that can help patients feel as good as they look and look as good as they feel. In 2021, Dr. Waples had the opportunity to begin a fellowship in Hormone Replacement Therapy and Longevity medicine, which she completed in 2022. Today she practices cutting-edge aesthetic, regenerative, and longevity medicine at RESTOR Medical Spa, teaches at RESTOR Academy, and works full-time as the Medical Director for RESTOR Medical Spa. In this episode, we discuss thinning skin and bruising in later life, what optimal levels of estrogen and testosterone look like in women, future medspa treatments on the horizon, and more!   Time Stamps:   (1:19) My Guest Today (6:50) Why A Medspa Practice? (8:45) The Reality of Entrepreneurship (11:25) Services Offered (16:10) Thinning Skin and Bruising (17:55) Why Testosterone Is Important For Women (22:45) Optimal Levels (33:10) Perimenopause (37:50) Too Much Estrogen? (39:55) Collagen Supplementation (51:35) Treatments On The Horizon (1:01:52) Where To Find Dr. Waples -------------------- https://www.restormedicalspa.com/   https://www.instagram.com/restormedicalspa/ -------------------- Instagram: https://www.instagram.com/carolcovinofitness/ -------------------- My YouTube Channel: http://youtube.com/@carolcovinofitness -------------------- My Book:  FINDING PURPOSE IN THE PAUSE

On this episode of Soundbites of the Annual Meeting, we talked to Stephen Kaminsky, PhD, professor of research in genetic medicine at Weill Cornell Medical College, and lead author of a phase 1 clinical trial of a new vaccine for cocaine addiction. In his conversation with ASGCT's Communications Committee Chair, Lynnea Olivarez, Dr. Kaminsky discusses: How the vaccine works and how its approach is different from other treatments Safety results from the unblinded data Implications this vaccine could have for other substance use disorders Listen and subscribe to the ASGCT Podcast Network so you don't miss any episodes!Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Yolanda Ragland. A leading podiatric surgeon specializing in bunion and hammer toe correction. Here are some key highlights and themes from the conversation:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Yolanda Ragland. A leading podiatric surgeon specializing in bunion and hammer toe correction. Here are some key highlights and themes from the conversation:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Yolanda Ragland. A leading podiatric surgeon specializing in bunion and hammer toe correction. Here are some key highlights and themes from the conversation:

Dr. Comen has dedicated her medical career to saving the lives of women. An award-winning, internationally sought-after clinician and physician-scientist, Dr. Comen works as a medical oncologist with a specialty in breast cancer at Memorial Sloan Kettering Cancer Center and is an assistant professor of medicine at Weill Cornell Medical College. She earned her BA in the history of science from Harvard College and her MD from Harvard Medical School, then completed her residency in Internal Medicine at Mount Sinai Hospital and her fellowship in oncology at Memorial Sloan Kettering Cancer Center. She's the author of All In Her Head: The Truth and Lies Early Medicine Taught Us About Women's Bodies and Why It Matters Today which we discuss on the show today. Join The Newsletter + Receive Your Free List of 52 Selfcare Tips Connect with Michele on Instagram RESOURCES MENTIONED Website: https://www.drelizabethcomen.com/ Instagram: https://www.instagram.com/drelizabethcomen/ Book: All In Her Head: The Truth and Lies Early Medicine Taught Us About Women's Bodies and Why It Matters Today If you enjoyed this interview, please take a moment to rate and review it on Apple podcasts. Your reviews are so appreciated! Not sure how to do it? Instructions are below. XO, Michele Rate + Review: 1. Click on this link 2. Click “View in Apple Podcasts” button 3. Make sure to “Follow” 4. Scroll down until you see “Ratings and Reviews” as shown below.

In this episode of Health Matters, we discuss what causes dizziness with Dr. Louise Klebanoff, a neurologist with NewYork-Presbyterian and Weill Cornell Medicine. Dr. Klebanoff explains the different types of dizziness, such as lightheadedness, vertigo, and gait instability. We also cover how to differentiate between these types, the potential causes, and  when to seek medical attention.___Dr. Louise Klebanoff, MD has been named the Chief of General Neurology and the Vice Chair of Operations for the Department of Neurology at Weill Cornell Medical College. She is also an Assistant Attending Neurologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.  Dr. Klebanoff received her medical degree from Georgetown University Medical Center, graduating first in her class, and went on to complete a residency in Neurology and a fellowship in Critical Care Neurology at NewYork-Presbyterian Hospital/Columbia University Medical Center.Prior to joining the Weill Cornell faculty, Dr. Klebanoff served as Attending Neurologist at Beth Israel Medical Center, where she also held leadership roles on various committees and served as the first female president of the Medical Board.Dr. Klebanoff is board certified in Psychiatry and Neurology. She is a member of the Alpha Omega Alpha honor society, the American Medical Association and the American Academy of Neurology.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine. To learn more visit: https://healthmatters.nyp.org

If you've ever avoided talking about death with a loved one because it felt too uncomfortable or culturally off-limits, episode 344 is for you. Dr. Cynthia X. Pan, a leading expert in end-of-life care, shares practical strategies for navigating these sensitive conversations with empathy and clarity. Learn how to approach topics like advanced directives and final wishes—especially across cultural lines—so you can honor your loved ones' values and find peace in knowing you did right by them.In This Episode, You Will Learn:(1:25) The evolution of palliative care(2:55) Ethics and cultural diversity in end-of-life conversations(4:30) Reframing death with dignity and celebration(5:51) The power of showing up(6:47) Family dynamics and grief during COVID(10:05) Why advanced directives matter(14:30) When systems ignore patient wishes(15:44) Navigating cultural resistance to end-of-life talk(21:56) Breaking death taboos and redefining goodbyeIn today's episode, I'm joined by Dr. Cynthia X. Pan, a board-certified physician in internal medicine, geriatrics, and hospice and palliative medicine. She holds a BA in Biology from Harvard and an MD from Stony Brook University School of Medicine. Dr. Pan completed her internal medicine residency at the University of Rochester and a geriatrics fellowship at Harvard Medical School's Division on Aging. She now serves as Chief of Geriatrics and Palliative Care Medicine and Designated Institutional Official for Graduate Medical Education at NewYork-Presbyterian Queens. A Professor at Weill Cornell Medical College, she educates future healthcare providers on palliative care, cultural humility, and communication. Fluent in Mandarin and Spanish, she brings a multicultural lens to patient-centered care.Throughout this episode, Dr. Pan uses her medical background and personal experiences to share both clinical insight and emotional depth. She reflects on working in one of the most culturally diverse regions in the U.S., where sensitive end-of-life conversations require compassion and cultural awareness. Through stories of caring for her father and mother-in-law, she highlights the importance of honoring patients' wishes. She also discusses how to approach taboo topics like death with respect and indirect communication—especially in communities where such discussions are avoided. Her guidance helps us embrace these moments with courage, clarity, and connection.Connect with Dr. Cynthia X. Pan:WebsiteInstagramLinkedInBook: Exit Strategies: Living Lessons from Dying People Let's Connect:WebsiteLinkedInFacebookInstagramTwitterThe Grief and Happiness Alliance Hosted on Acast. See acast.com/privacy for more information.

In this episode, Bob and Peter discuss Stem Cells 101, why it's not available in America, and the importance of stem cell treatment for humanity.  Recorded on Nov 21st, 2024 Views are my own thoughts; not Financial, Medical, or Legal Advice. Dr. Robert Hariri is the Chairman, Founder, and CEO of Celularity, Inc., a leader in human cellular therapeutics developing placental stem cell-based therapies for cancer, autoimmune diseases, and other conditions. A distinguished surgeon, scientist, and entrepreneur, Dr. Hariri is known for discovering pluripotent stem cells from the human placenta and holds over 170 patents in the field. He founded Anthogenesis Corporation, later acquired by Celgene, and co-founded Human Longevity, Inc. Dr. Hariri, an MD and PhD graduate from Cornell University, serves as an Adjunct Professor of Neurosurgery at Weill Cornell Medical College and has earned prestigious honors, including the Pontifical Medal for Innovation and two Thomas Alva Edison Awards. His groundbreaking work continues to shape regenerative medicine and immuno-oncology. He's also a founding partner of Fountain Life. Learn more about Celularity: https://celularity.com/  Lifebank USA: https://www.lifebankusa.com/  Get my Longevity Guidebook here: https://qr.diamandis.com/book-audiopodcast ____________ I only endorse products and services I personally use. To see what they are, please support this podcast by checking out our sponsors:  Get started with Fountain Life and become the CEO of your health: https://fountainlife.com/peter/ AI-powered precision diagnosis you NEED for a healthy gut: https://www.viome.com/peter  Get 15% off OneSkin with the code PETER at  https://www.oneskin.co/ #oneskinpod _____________ I send weekly emails with the latest insights and trends on today's and tomorrow's exponential technologies. Stay ahead of the curve, and sign up now: Tech Blog _____________ Connect With Peter: Twitter Instagram Youtube Moonshots

How often do you clean your cellphone? Chances are you don't do it often unless the screen starts to get a little gross. This episode begins with some interesting intel that will have you cleaning your phone much more often than you likely do now. https://www.statefoodsafety.com/Resources/Resources/the-dirty-cell-phone-25-127-bacteria-per-square-inch# We all face big challenges in life. Yet, when it comes to the things that really take a toll and wear us down, it's the little hassles and frustrations that do the most damage. Your ability to handle the little things life throws at you is what determines the quality of your life, according to my guest Dr. Samantha Boardman, a clinical instructor in psychiatry and attending psychiatrist at Weill Cornell Medical College. She is founder of https://www.PositivePrescription.com and author of the book Everyday Vitality: Turning Stress into Strength (https://amzn.to/3szCZHB). Listen as she offers some extremely practical strategies to navigate the daily troubles we all face without letting them take such a big toll on you. Before you ever walk into an Italian, Mexican or Japanese, you already have a pretty good idea of what will be on the menu. Yet, when it comes to American food, is there such a thing as American cuisine? What do people in other countries think of when they think of American food? That's what Paul Freedman decided to explore. And what he found is fascinating. Paul is a history professor at Yale University and author of the book American Cuisine: And How it Got This Way (https://amzn.to/3JjoO03). Listen as he reveals some of the history and stories that shaped what Americans eat today. Is being happy good for your health? The answer is yes, but not necessarily in the way you think. Listen as I explain what researchers found that will really make you want to be happy and stay happy. https://www.hsph.harvard.edu/news/magazine/happiness-stress-heart-disease PLEASE SUPPORT OUR SPONSORS!!! INDEED:  Get a $75 SPONSORED JOB CREDIT to get your jobs more visibility at https://Indeed.com/SOMETHING  Support our show by saying you heard about Indeed on this podcast.  Terms & conditions apply. AURA: Save on the perfect gift by visiting https://AuraFrames.com to get $35-off Aura's best-selling Carver Mat frames by using promo code SOMETHING at checkout! SHOPIFY:  Sign up for a $1 per-month trial period at https://Shopify.com/sysk . Go to SHOPIFY.com/sysk to grow your business – no matter what stage you're in! MINT MOBILE: Cut your wireless bill to $15 a month at https://MintMobile.com/something! $45 upfront payment required (equivalent to $15/mo.).  New customers on first 3 month plan only. Additional taxes, fees, & restrictions apply. HERS: Hers is changing women's healthcare by providing access to GLP-1 weekly injections with the same active ingredient as Ozempic and Wegovy, as well as oral medication kits. Start your free online visit today at https://forhers.com/sysk DELL: It's your last chance to snag Dell Technologies' lowest prices of the year before the holidays! If you've been waiting for an AI-ready PC, this is their biggest sale of the year! Shop now at https://Dell.com/deals PROGRESSIVE: The Name Your Price tool from Progressive can help you save on car insurance! You just tell Progressive what you want to pay and get options within your budget. Try it today at https://Progressive.com Learn more about your ad choices. Visit megaphone.fm/adchoices